Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

Opinion
Video

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Jean L. Koff, MD, MS
Hannah Walker-Mimms, MS